EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Improving cardiovascular risk stratification through the derivation and validation of an elevated triglyceride‐glucose index

Georgios Mavraganis, Georgios Georgiopoulos, Stavros Athanasopoulos iD, Dimitrios Terentes-Printzios, Georgios Zervas, Christina Konstantaki, Maria Eleni Koilakou, Sofia-Panagiota Giannakopoulou, Maria-Angeliki Dimopoulou, Christina Chrysochoou, Konstantinos Tsioufis, Christos Pitsavos und 5 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70270 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Georgios Mavraganis und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece. Hauptthemen laut MEDLINE: Triglycerides, Blood Glucose, Cardiovascular Diseases, Atherosclerosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Triglyceride‐glucose (TyG) index, is an emerging prognostic biomarker in atherosclerotic cardiovascular disease (ASCVD). Validation of its clinical value and of clinically relevant prognostic cut‐off, remains an unmet need to integrate TyG into primary prevention protocols.

Methods

To assess the clinical applicability of TyG, a composite of cardiovascular mortality, myocardial infarction, coronary revascularization or stroke was used as the primary endpoint in a general population cohort (ATTICA cohort, n = 1677, derivation cohort). Next, we derived an optimal prognostic TyG cut‐off and externally validated it in a primary prevention cohort ( n = 1237). To assess the clinical value of TyG, we analysed 1170 consecutively recruited patients from an ongoing registry aiming to stratify ASCVD risk (Athens Cardiometabolic Cohort) and assessed indices of subclinical arterial injury and progression of atherosclerosis. The TyG index was calculated by the formula: ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2].

Results

TyG index was independently associated with increased CVD events in the derivation cohort (HR = 1.33, p = 0.020). The incremental value of a derived optimal cut‐off of 8.46 over SCORE2 was confirmed in both derivation and validation cohorts [net reclassification index (NRI) = 0.668 and 0.469 respectively, Delta Harrell's C index = 0.054 and 0.044 respectively, p < 0.05 for all]. Elevated TyG index was associated with more diseased vascular beds (OR = 2.00, 95% CI 1.24–3.24), progression of subclinical carotid atherosclerosis (OR = 2.99, 95% CI 1.10–8.17) at follow‐up and established ASCVD ( p < 0.05 for all).

Conclusions

TyG is associated with increased prevalence and progression of subclinical and clinically overt ASCVD. In individuals assessed for primary prevention a TyG≥8.46 may serve as a risk enhancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriglyceridesBlood GlucoseCardiovascular DiseasesAtherosclerosisHumansMaleFemaleMiddle AgedAgedRisk AssessmentBiomarkersPrognosisCohort StudiesHeart Disease Risk FactorsRisk Factors

Stichwörter der Autor:innen

cardiovascular diseasecohort studyinsulin resistancepopulation study

Substanzen

TriglyceridesBlood GlucoseBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
  • Department of Physiology, School of Medicine, University of Patras, Patras, Greece.
  • First Department of Cardiology, Hippokration General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece.
  • First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
  • Department of Cardiovascular Research, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

ORCID-Profile: Stavros Athanasopoulos, Konstantinos Stellos, Demosthenes Panagiotakos, Kimon Stamatelopoulos

Zitieren

APA

Mavraganis, G., Georgiopoulos, G., Athanasopoulos, S., Terentes-Printzios, D., Zervas, G., Konstantaki, C., Koilakou, M. E., Giannakopoulou, S. P., Dimopoulou, M. A., Chrysochoou, C., Tsioufis, K., Pitsavos, C., Liberopoulos, E., Stellos, K., Vlachopoulos, C., Panagiotakos, D., & Stamatelopoulos, K. (2026). Improving cardiovascular risk stratification through the derivation and validation of an elevated triglyceride‐glucose index. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70270

Vancouver

Mavraganis G, Georgiopoulos G, Athanasopoulos S, Terentes-Printzios D, Zervas G, Konstantaki C, et al. Improving cardiovascular risk stratification through the derivation and validation of an elevated triglyceride‐glucose index. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70270

BibTeX
@article{Mavraganis2026,
  author = {Mavraganis, Georgios and Georgiopoulos, Georgios and Athanasopoulos, Stavros and Terentes-Printzios, Dimitrios and Zervas, Georgios and Konstantaki, Christina and Koilakou, Maria Eleni and Giannakopoulou, Sofia-Panagiota and Dimopoulou, Maria-Angeliki and Chrysochoou, Christina and Tsioufis, Konstantinos and Pitsavos, Christos and Liberopoulos, Evangelos and Stellos, Konstantinos and Vlachopoulos, Charalambos and Panagiotakos, Demosthenes and Stamatelopoulos, Kimon},
  title = {Improving cardiovascular risk stratification through the derivation and validation of an elevated triglyceride‐glucose index},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70270}
}
Kostenlos starten →